Trial Information

Summary: SWOG S0226 "Phase III randomized trial of anastrozole versus anastrozole and fluvestrant as first line therapy for post menopausal women with metastatic breast cancer" Eligible patients will be randomized into one of two study groups: Arm 1 Anastrozole crossover to fulvestrant Arm 2 Anastrozole and fulvestrant

The purpose of this study is to find out what effects (good or bad) the combination of hormonal agents anastrozole and fulvestrant have over anastrozole alone on the patient or the breast cancer.

690 women will take part in this study.

Patient Inclusion Criteria

• Patients must be female with a pahtologically confirmed diagnosis of mestatic breast cancer or multiple sites of new disease that is clinically obvious mestatic disease
• Patients must be postmenopausal
• Patients must have measureable or non-measureable disease.
• Patients must be ER and/or PR positive.

Patient Exclusion Criteria

• Patients with known brain or CNS metastases are not eligible.
• Patients who are receiving chemotherapy or hormone therapy.
• Patients known to be HIV positive.

For more information,

If you would like to learn more about participating in this study, please send an e-mail message using the form below.